The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular u
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
대표청구항▼
The invention claimed is: 1. A method of treating a subject six to twelve years of age having attention deficit hyperactivity disorder, said method comprising orally administering to said subject a pharmaceutically effective amount of L-lysine-d-amphetamine or a pharmaceutically acceptable salt the
The invention claimed is: 1. A method of treating a subject six to twelve years of age having attention deficit hyperactivity disorder, said method comprising orally administering to said subject a pharmaceutically effective amount of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof. 2. A method as defined in claim 1, wherein said attention deficit hyperactivity disorder is of the combined type. 3. A method as defined in claim 1, wherein said attention deficit hyperactivity disorder is of the hyperactive-impulsive type. 4. A method as defined in claim 1, wherein said subject is administered a mesylate salt of L-lysine-d-amphetamine. 5. A method as defined in claim 1, wherein said subject is administered L-lysine-d-amphetamine dimesylate. 6. A method as defined in claim 1, wherein said subject is administered 30 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof once daily. 7. A method as defined in claim 1, wherein said subject is administered 50 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof once daily. 8. A method as defined in claim 1, wherein said subject is administered 70 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof once daily. 9. A method as defined in claim 1, wherein said L-lysine-d-amphetamine is administered in a pharmaceutical composition comprising said L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive suitable for oral administration. 10. A method as defined in claim 9, wherein therapeutic effects of L-lysine-d-amphetamine occur within two hours post administration and continue through twelve hours post administration. 11. A method as defined in claim 9, wherein said administration provides a TMAX of d-amphetamine approximately 3.5 hours following administration of L-lysine-d-amphetamine to said subject and a TMAX of approximately 1 hour of L-lysine-d-amphetamine after administration of L-lysine-d-amphetamine to said subject. 12. A method as defined in claim 9, wherein said d-amphetamine exhibits linear pharmacokinetics after administration. 13. A method of treating symptoms of attention deficit hyperactivity disorder in a subject six to twelve years of age in need thereof, said method comprising orally administering to said subject a pharmaceutically effective amount of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof; whereby one or more of said symptoms diminish in said subject in a statistically significant amount as compared to a subject not receiving treatment of symptoms of attention deficit hyperactivity disorder. 14. A method as defined in claim 13, wherein said attention deficit hyperactivity disorder is of the combined type. 15. A method as defined in claim 13, wherein said attention deficit hyperactivity disorder is of the hyperactive-impulsive type. 16. A method as defined in claim 13, wherein said symptoms are included in the DSM-IV criteria for attention deficit hyperactivity disorder. 17. A method as defined in claim 13, wherein said diminished symptom is deportment. 18. A method as defined in claim 13, wherein said diminished symptom is inattention. 19. A method as defined in claim 13, wherein said diminishment is measured using the ADHD ratings scale. 20. A method as defined in claim 19, wherein said diminishment is measured at a study end point. 21. A method as defined in claim 13, wherein said diminishment is measured using the Connor's Parents Rating Scale. 22. A method as defined in claim 21, wherein said diminishment is measured at a study end point. 23. A method as defined in claim 13, wherein said diminishment is measured using the SKAMP Deportment Rating Scale. 24. A method as defined in claim 23, where said diminishment is measured at a study end point. 25. A method as defined in claim 13, wherein said subject is administered 30 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof once daily. 26. A method as defined in claim 13, wherein said subject is administered 50 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof once daily. 27. A method as defined in claim 13, wherein said subject is administered 70 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof once daily.
Buechler Kenneth F. (San Diego CA) Noar Joseph B. (Solana Beach CA) Moi Si S. (Escondido CA), Amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels.
Miyazaki Jinsei (Higashiosaka JPX) Taketani Makoto (Ashiya JPX) Mitsumata Tadayasu (Hirakata JPX), Amphetamine protein complex as immunogen for obtaining antibodies specific to methamphetamine.
Ekwuribe Nnochiri ; Ramaswamy Muthukumar ; Rajagopalan Jayanthi Sethuraman, Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same.
Arimilli Murty N. ; Cundy Kenneth C. ; Dougherty Joseph P. ; Kim Choung U. ; Oliyai Reza ; Stella Valentino J., Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability.
Kohn Joachim B. (Highland Park NJ) Langer Robert S. (Somerville MA) Niemi Steven M. (Sudbury MA) Fox James G. (Littleton MA), Biodegradable polymeric drug delivery system with adjuvant activity.
Bichon Daniel (Les Lieux dits “Les Chenevires”16 ; rue de Vallard 74240 Gaillard FRX) Lamy Bernard (Chemin Jules Vuy 23 1227 Carouge CHX), Biodegradable polypeptide and the use thereof for the gradual release of drugs.
Pardridge William M. (Pacific Palisades CA) Schimmel Paul R. (Lexington MA), Chimeric peptides for neuropeptide delivery through the blood-brain barrier.
Balasubramanium Ambikaipakan ; Chance William T., Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm.
Anderson David C. (Seattle WA) Morgan ; Jr. A. Charles (Edmonds WA) Abrams Paul G. (Seattle WA) Fritzberg Alan R. (Edmonds WA) Nichols Everett J. (Seattle WA), Covalently-linked complexes and methods for enhanced cytotoxicity and imaging.
Stella Valentino J. (Lawrence KS) Mathew Abraham E. (Lenexa KS), Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof.
Phillips Christopher P. (Brandamore PA) Snow Robert A. (West Chester PA), Lyophilized polyethylene oxide modified protein and polypeptide complexes with cyclodextrin.
Poduslo Joseph F. (5719 St. Mary\s Dr. NW Rochester MN 55901) Curran Geoffrey L. (629 23rd St. NE Rochester MN 55906), Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents.
Deming, Timothy J.; Yu, Miaoer; Curtin, Scott A.; Hwang, Jungyeon; Wyrsta, Michael D.; Nowak, Andrew; Seidel, Scott W., Methods and compositions for controlled polypeptide synthesis.
Florvall Gosta Lennart (Sodertalje SW) Ross Svante Bertil (Sodertalje SW) Ogren Sven-Ove (Sodertalje SW), Pharmaceutical compositions containing an amphetamine derivative for the alleviation of anxiety or treatment of depressi.
Zalipsky Samuel (Princeton NJ) Bolikal Durgadas (Edison NJ) Nathan Aruna (Piscataway NJ) Kohn Joachim B. (Highland Park NJ), Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon.
Janmey Paul A. ; Cunningham C. Casey ; Hartwig John H. ; Stossel Thomas P. ; Vegner Roland,LVX, Polyphoshoinositide binding peptides for intracellular drug delivery.
Gao, Feng; Miotto, Jahanara, Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain.
Yager Paul ; Gelb Michael H. ; Carlson Paul A. ; Lee Kyujin C. ; Lukyanov Anatoly N. ; Goldstein Alex S., Therapeutic delivery using compounds self-assembled into high axial ratio microstructures.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Peterson Robert V. (Murray UT) Anderson James M. (Cleveland Heights OH) Gregonis Donald E. (Salt Lake City UT) Kim Sunj-Wan (Salt Lake City UT) Feijen Jan (Hengelo NLX), Time-release chemical delivery system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.